Cyclin D1 Gene G870A Variants and Primary Brain Tumors

Zeybek, Ümit; Yaylım, İlhan; Ozkan, Nazli Ezgi; Korkmaz, Gurbet; Turan, Saime; Kafadar, Didem; Cacina, Canan; Kafadar, Ali

doi:10.7314/apjcp.2013.14.7.4101

Cited by 19 publications

(20 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationships between the G870A SNP and excessive CCND1 activity, as well as numerous human tumors, have been studied in recent years, including primary brain tumors, bladder cancer, colorectal cancer, esophageal cancer, hepatocellular carcinoma, leukemia, and breast cancer (Akkiz et al, 2010;Zhuo et al, 2012;Bedewy et al, 2013;Sameer et al, 2013;Zeybek et al, 2013;Li et al, 2014). Among these, the numerous relevant epidemiologic studies investigating the relationship between the CCND1 G870A variant and hepatocellular carcinoma (Zhang et al, 2002;Pakakasama et al, 2004;Akkiz et al, 2010;Hu et al, 2014) or leukemia (Howe and Lynas, 2001;Hou et al, 2005;Bedewy et al 2013) have yielded conflicting and controversial results.…”

Section: Introductionmentioning

confidence: 99%

Cyclin D1 G870A gene polymorphism and risk of leukemia and hepatocellular carcinoma: a meta-analysis

Zhao¹,

He²,

Wang³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Cyclin D1 (CCND1) is a key protein involved in cellcycle regulation, and the CCND1 G870A polymorphism is associated with many types of malignancy. Studies examining the associations between this G870A polymorphism and susceptibility to leukemia and hepatocellular carcinoma (HCC) have shown inconsistent results. Therefore, we conducted a meta-analysis to clarify these associations. A search of the PubMed database yielded 7 relevant articles: 3 pertaining to leukemia and 4 to HCC. The odds ratios (ORs) from individual studies were pooled using a fixed or random-effect model. A significant association was observed between the CCND1 G870A variant and leukemia under the allele contrast model [P = 0.003, OR = 1.49, 95% confidence interval (CI) = 1.15-1.95], the homozygote contrast model (P = 0.003, OR = 2.30, 95%CI = 1.34-3.96), and the recessive model (P = 0.002, OR = 2.03, 95%CI = 1.29-3.21). A significant association was observed between this variant and HCC under the recessive model (P = Y. Zhao et al. 5172©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 5171-5180 (2015) 0.0006, OR = 1.62, 95%CI = 1.23-2.14), the dominant model (P = 0.002, OR = 1.59, 95%CI = 1.19-2.14), the homozygote contrast model (P < 0.0001, OR = 2.06, 95%CI = 1.45-2.94), and the allele contrast model (P < 0.0001, OR = 1.43, 95%CI = 1.20-1.69). Our findings suggest that heritable CCND1 status may influence the risk of developing leukemia and HCC, and that more attention should be given to carriers of these susceptibility genes.

show abstract

Section: Introductionmentioning

confidence: 99%

Cyclin D1 G870A gene polymorphism and risk of leukemia and hepatocellular carcinoma: a meta-analysis

Zhao¹,

He²,

Wang³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Gliomas are the most common malignant tumors in the central nervous system, accounting for approximately 50% of primary brain tumors (Zeybek et al, 2013). These tumors are characterized by rapid invasive growth into surrounding brain parenchyma, and thus result in a poor prognosis, despite advances in surgical resection, radiotherapy and chemotherapy (Ohgaki et al, 2005;Wu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

MAGED4 Expression in Glioma and Upregulation in Glioma Cell Lines with 5-Aza-2'-Deoxycytidine Treatment

Zhang¹,

Shen²,

Xie³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Melanoma-associated antigen (MAGE) family genes have been considered as potentially promising targets for anticancer immunotherapy. MAGED4 was originally identified as a glioma-specific antigen. Current knowledge about MAGED4 expression in glioma is only based on mRNA analysis and MAGED4 protein expression has not been elucidated. In the present study, we investigated this point and found that MAGED4 mRNA and protein were absent or very lowly expressed in various normal tissues and glioma cell line SHG44, but overexpressed in glioma cell lines A172,U251,U87-MG as well as glioma tissues, with significant heterogeneity. Furthermore, MAGED4 protein expression was positively correlated with the glioma type and grade. We also found that the expression of MAGED4 inversely correlated with the overall methylation status of the MAGED4 promoter CpG island. Furthermore, when SHG44 and A172 with higher methylation were treated with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-AZA-CdR) reactivation of MAGED4 mRNA was mediated by significant demethylation in SHG44 instead of A172. However, 5-AZA-CdR treatment had no effect on MAGED4 protein in both SHG44 and A172 cells. In conclusion, MAGED4 is frequently and highly expressed in glioma and is partly regulated by DNA methylation. The results suggest that MAGED4 might be a promising target for glioma immunotherapy combined with 5-AZA-CdR to enhance its expression and eliminate intratumor heterogeneity.

show abstract

“…High incidences of tumors of the brain and nervous system have been noted in Brazil, the US and the Hawaiian islands among the white population, Canada , Italy Poland, Finland an other European countries, and low incidence was found in Africa and Asia (Cheng et al, 2013;Igissinov et al, 2013;Jazayeri et al, 2013;Liang et al, 2013;Zeybek et al, 2013;Zhang et al, 2013). GC is a special kind of tumor of CNS, for which invasive growth is its typical biological behavior and the key factor of high reoccurrence rate and short survival time.…”

Section: Discussionmentioning

confidence: 99%

Clinical Manifestations and Imaging Characteristics of Gliomatosis Cerebri with Pathological Confirmation

Zhang

Li²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cyclin D1 Gene G870A Variants and Primary Brain Tumors

Cited by 19 publications

References 55 publications

Cyclin D1 G870A gene polymorphism and risk of leukemia and hepatocellular carcinoma: a meta-analysis

Cyclin D1 G870A gene polymorphism and risk of leukemia and hepatocellular carcinoma: a meta-analysis

MAGED4 Expression in Glioma and Upregulation in Glioma Cell Lines with 5-Aza-2'-Deoxycytidine Treatment

Clinical Manifestations and Imaging Characteristics of Gliomatosis Cerebri with Pathological Confirmation

Contact Info

Product

Resources

About